Aims and objectives
Gleason Score is recognized as an effective clinical predictor to define prostate cancer aggressiveness.
[1] Gleason 7 tumors include those with a predominant Gleason 4 pattern (Gleason 4 + 3) and a predominant Gleason 3 pattern (Gleason 3 + 4),
and Gleason 4+3 tumors were at increased risk for disease progression,
recurrence and prostate cancer specific mortality.
[2,3] However,
the Gleason scores determined from biopsies often differ from immediate repeat biopsies and postoperative pathological.
[4] We aim to investigate whether Radiomics have the ability to...
Methods and materials
Prostate cancer patients with identified postoperative pathological results and was collected continuously from 2008 to 2016 in Wuxi People’s Hospital.
All patients were scanned at a single institution with 3.0-T MR scanners (MAGNETOM Verio,
Siemens Healthcare,
Erlangen,
Germany) using pelvic phased-array coils.
In total,
207 patients with GS=7 were identified and involved in this study,
which GS (4+3)(Fig.1) vs.
GS (3+4)(Fig.2)close to 1:1.
For every standard prostatic MRI examination conducted in our hospital,
the protocol included a combination of T1-weighted imaging (T1WI),
T2WI,
DWI and...
Results
In total,
4028 Radiomics features were extracted from multiparametric MR images.
After feature selection,
10 features left for further model building.
The accuracy of Radiomic features based on multiparametric MRI were 0.96 (95% CI: 0.95-0.98) on the training set,and 0.93 (95% CI: 0.90-0.96) on the validation set (Fig3).
Conclusion
In spite of same GS and indistinguishable Imaging manifestations,
obvious differences exist between two subgroups (GS 4+3 vs.
3+4).
Radiomics features based on multiparametric MR images (T2WI,
DWI and ADC) were proved to have the ability to identify differences in pathological levels and could provide a preoperative noninvasive clinical tool for doctors.
Personal information
M.
Xu,
MD
Imaging Center,
Wuxi People’s Hospital,
Nanjing Medical University,
No.
299,
Qingyang Road,
Liangxi District,
Wuxi,
Jiangsu Province,
214023,
China
References
Mottet N,
Bellmunt J,
Bolla M,
et al.
EAU-ESTRO-SIOG guidelines on prostate cancer.
Part 1: screening,
diagnosis,
and local treatment with curative intent[J].
European urology,
2017,
71(4): 618-629.
Wright J L,
Salinas C A,
Lin D W,
et al.
Differences in prostate cancer outcomes between cases with Gleason 4+ 3 and Gleason 3+ 4 tumors in a population-based cohort[J].
The Journal of urology,
2009,
182(6): 2702.
Cooperberg M R,
Cowan J E,
Hilton J F,
et al.
Outcomes of active surveillance for men with intermediate-risk...